Cancer Center Support Grant

项目摘要 自2012年对该癌症中心支持拨款(CCSG)进行上次竞争性审查以来，NCI指定的 珀尔穆特癌症中心(PCC)，前身为纽约大学癌症研究所，经受住了 超级风暴桑迪，出现了深刻的转型扩张期。由一个 来自劳里和艾萨克·珀尔穆特的变革性礼物，来自纽约大学的新的和加强的机构支持 兰贡健康系统(NYULH)和新的董事，我们已经彻底改革了我们的领导团队，扩大了我们的 临床和研究设施，并制定了新的战略愿景并开始实施新的战略 计划一下。在这个计划的指导下，我们的科学计划和共享资源进行了重组，我们 启动了一项重大招聘活动，产生了12名新的领导层和/或高级教职员工 新成员，其他15名新的癌症中心教职员工，以及总共68名新成员。在修订中，更多 由于标准严格，会员人数已精简至180名正式会员和56名准会员。成员 作为5个科学项目的一部分进行研究，癌症基因组动力学，癌细胞生物学，肿瘤 免疫学、黑色素瘤或流行病学和癌症控制，由10个共享资源和2个 发展共享资源。我们的临床试验办公室已经进行了重组，并进行了大幅扩充 在新的领导下，一个新的第一阶段机组已经启用。随后，试验可用性、质量和应计费用 增加了，而开庭审理的时间明显减少。与我们增加的 考虑到地理范围和患者人数，我们重新定义并扩大了我们的集水区。得到了 在纽约大学朗格尼医学院和纽约大学人口健康学院设立一个新的人口健康系 全球公共卫生在纽约大学主校区，我们的人口科学研究在广度上有所增加 和质量。最重要的是，我们的实验室科学家已经做出了改变范式的发现，我们的临床医生 领导了多项改变实践的试验，我们的人口科学家对 癌症的原因和如何控制这种疾病，促进了重大的公共卫生政策变化和 倡议，并建立了新的社区外展计划，以解决特定的癌症负担和 我们集水区的健康差距。尽管PCC位于一个城市，还有另外四个NCI指定的 癌症中心，我们的集水区与其他地区有很大的不同：我们是降低 曼哈顿，并已扩展到布鲁克林，纽约市最大和增长最快的行政区，作为 以及皇后区和长岛。

Project Summary Since the last competitive review of this Cancer Center Support Grant (CCSG) in 2012, the NCI-designated Perlmutter Cancer Center (PCC), previously NYU Cancer Institute, has weathered the devastation of Superstorm Sandy and emerged into a period of profound transformation and expansion. Propelled by a transformative gift from Laurie and Isaac Perlmutter, renewed and enhanced institutional support from the NYU Langone Health system (NYULH) and a new Director, we have overhauled our leadership team, expanded our clinical and research facilities, and developed a new strategic vision and began implementing a new Strategic Plan. Guided by this plan, our Scientific Programs and Shared Resources have been restructured, and we embarked on a major recruitment campaign that has yielded 12 additional new leadership and/or senior faculty recruits, 15 other new cancer center faculty recruits, and 68 new members overall. Under revised, more stringent criteria, membership has been streamlined to 180 full members and 56 associate members. Members carry out research as part of 5 Scientific Programs, Cancer Genome Dynamics, Cancer Cell Biology, Tumor Immunology, Melanoma, or Epidemiology and Cancer Control, assisted by 10 Shared Resources and 2 Developing Shared Resources. Our clinical trials office has been reorganized and substantially expanded under new leadership and a new Phase I unit has opened. Subsequently, trial availability, quality, and accrual have increased, while the time to trial opening has been markedly reduced. In line with our increased geographic scope and patient population, we have redefined and enlarged our catchment area. Aided by the creation of a new Department of Population Health at NYU Langone School of Medicine and the College of Global Public Health at the NYU main campus, our Population Sciences research has increased in breadth and quality. Most importantly, our laboratory scientists have made paradigm-shifting discoveries, our clinicians have led multiple practice-changing trials, and our population scientists have yielded new insights into the causes of cancer and how to control the disease, contributed to major public health policy changes and initiatives, and established new community outreach programs that address the specific cancer burdens and health disparities in our catchment area. Although PCC is located in a city with four other NCI-designated cancer centers, our catchment area differs substantially from the others: we are the major provider to lower Manhattan, and have expanded into Brooklyn, the largest and fastest growing borough in New York City, as well as to Queens and Long Island.